RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alpha(v)beta(3)-expressing endothelial cells

Astrid Leegte - Schraa, R.J Kok, S.M. Botter, S Withoff, D.K F Meijer, Lou de Leij, G Molema

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
Original languageEnglish
Pages (from-to)279 - 285
Number of pages7
JournalInternational Journal of Cancer
Volume112
Issue number2
DOIs
Publication statusPublished - Nov-2004

Keywords

  • immunotherapy
  • vascular targeting
  • cytotoxic T lymphocytes
  • alpha(v)beta(3) integrin
  • RGD peptide
  • BISPECIFIC ANTIBODY
  • TUMOR VASCULATURE
  • MODIFIED PROTEINS
  • GROWTH
  • INTEGRINS
  • PEPTIDES
  • CANCER
  • DELIVERY
  • THERAPY
  • VACCINE

Cite this